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Abstract
Rationale: Nerve growth factor (NGF) promotes angiogenesis and cardiomyocyte survival,
which are both desirable for postinfarction myocardial healing. Nonetheless, the NGF potential for
cardiac repair has never been investigated.
Objective: To define expression and localization of NGF and its high-affinity receptor TrkA
(tropomyosin-related receptor A) in the human infarcted heart and to investigate the cardiac roles
of both endogenous and engineered NGF using a mouse model of myocardial infarction (MI).
Methods and Results: Immunostaining for NGF and TrkA was performed on heart samples
from humans deceased of MI or unrelated pathologies. To study the post-MI functions of
endogenous NGF, a NGF-neutralizing antibody (Ab-NGF) or nonimmune IgG (control) was given
to MI mice. To investigate the NGF therapeutic potential, human NGF gene or control (empty
vector) was delivered to the murine periinfarct myocardium. Results indicate that NGF is present
in the infarcted human heart. Both cardiomyocytes and endothelial cells (ECs) possess TrkA,
which suggests NGF cardiovascular actions in humans. In MI mice, Ab-NGF abrogated native
reparative angiogenesis, increased EC and cardiomyocyte apoptosis and worsened cardiac
function. Conversely, NGF gene transfer ameliorated EC and cardiomyocyte survival, promoted
neovascularization and improved myocardial blood flow and cardiac function. The prosurvival/
proangiogenic Akt/Foxo pathway mediated the therapeutic benefits of NGF transfer. Moreover,
NGF overexpression increased stem cell factor (the c-kit receptor ligand) expression, which
translated in higher myocardial abundance of c-kitpos progenitor cells in NGF-engineered hearts.
Conclusions: NGF elicits pleiotropic beneficial actions in the post-MI heart. NGF should be
considered as a candidate for therapeutic cardiac regeneration.
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Myocardial infarction (MI) remains a major cause of morbidity and mortality and it is
responsible for about one third of heart failure cases worldwide.1 Sudden occlusion of a
major coronary artery and acute myocardial ischemia causes rapid death of cardiomyocytes
and vascular cells in the area of interest.2 Loss of cardiomyocytes and vasculature leads to
progressive fibrous replacement of myocardium, hypertrophic growth of the spared
myocardium, and left ventricular (LV) dilatation. Maladaptive ventricular remodeling
contributes to post-MI heart failure,3 and prognosis of heart failure patients is still poor.4
Myocardial ischemia triggers a spontaneous angiogenic response aimed at reestablishing
myocardial blood flow. Nonetheless, this protective response is usually not sufficient.5
Nerve growth factor (NGF) is a secreted glycoprotein of the neurotrophin family. NGF
elicits its biological effects mainly by binding the high-affinity TrkA receptor (tropomyosin-
related receptor A, which is a tyrosine kinase). We and others previously demonstrated that
NGF, via TrkA, promotes angiogenesis and endothelial cells (ECs) survival through a
mechanism involving the serine/threonine kinase Akt (also known as protein kinase B).6,7
Akt regulates a variety of cellular functions and it is strongly implicated in angiogenesis and
cell survival.8 We also demonstrated that cultured cardiomyocytes express TrkA and release
NGF.9 Moreover, NGF is an autocrine prosurvival factor for the cardiomyocyte through the
Akt/Forkhead box-O transcription factors (Foxo) pathway.9 Foxo factors stimulate cell
death and are downstream targets of Akt.10 Akt-mediated phosphorylation regulates
Foxo-3a subcellular localization and activity: unphosphorylated Foxo-3a resides in the
nucleus, whereas Foxo-3a phosphorylation leads to its nuclear exclusion and inactivation.11
Moreover, Foxo-1 and -3a represses angiogenesis by downregulating endothelial nitric oxide
synthase.12
Experimental evidences suggest that myocardial repair is, at least in part, dependent on c-kit
receptor–expressing (c-kitpos) progenitor cell populations.13-15 Lineage negative (Linneg) c-
kitpos cells are increased in the infarcted heart and heart-derived Linnegc-kitpos cells can
generate new vascular cells and myocytes both in vivo and in vitro.13 Activation of the c-kit
receptor is mediated by its ligand stem cell factor (SCF), a cytokine that exists in soluble or
membrane-associated form.16 The membrane-bound SCF isoform, which is predominant in
vivo, is able to induce more persistent c-kit activation.17 It was recently reported that
transgenic mice with cardiomyocyte-specific membrane-associated SCF over-expression
have improved post-MI cardiac function and angiogenesis in comparison to wild types.18
In the present study, we firstly investigated NGF and TrkA expression in the human
infarcted heart. We then evaluated the functions of endogenous NGF and the therapeutic
potential of its overexpression in the post-MI heart using mice. Finally, we studied the
potential involvement of the Akt/Foxo-3a pathway and of cardiac progenitor cell
populations, with particular emphasis on Linnegc-kitpos cells, in the NGF-mediated cardiac
repair after MI.
Methods
An expanded Methods section is available in the Online Data Supplement at http://
circres.ahajournals.org.
Immunohistochemical Analysis of Human Cardiac Samples
Cardiac samples were collected at autopsy from human subjects (described in Online Table
I) died after MI or causes other than cardiovascular diseases. NGF expression and TrkA
expression and localization in cardiomyocytes and endothelial cells (ECs) were determined.
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MI Protocol in Mice
In vivo experiments were performed in accordance with the Guide for the Care and Use of
Laboratory Animals prepared by the Institute of Laboratory Animal Resources and with the
prior approval of the UK Home Office and the University of Bristol. MI was induced in
anesthetized CD1 male mice, as described.19 To study the actions of endogenous NGF in
the postinfarct myocardium, mice received IP a goat-raised NGF-neutralizing antibody (Ab-
NGF) or control non immune goat-IgG.6,9 To investigate the therapeutic potential of local
NGF overexpression, mice were injected in the periinfarct myocardium with an adenoviral
vector carrying human NGF (V5-tagged) or Ad.Null (control).9 Sham-operated mice
received Ad.Null. Survival curves of mice enrolled in the NGF neutralization and the hNGF
gene therapy protocols were studied. To verify whether NGF-induced therapeutic effect
depends on the Akt/Foxo-3a pathway activation, additional MI mice were injected in the
periinfarct with a Foxo-3a mutant form which is resistant to Akt phosphorylation
(Ad.AAAFoxo3a) or Ad.Null in combination with Ad.hNGF or Ad.Null. LV function and
dimensions were measured by echocardiography at 14 and 30 days post-MI. LV function at
14 days was additionally measured with a miniaturized 1.4F transducer Millar tip-catheter.
Myocardial blood flow (mL/min per gram of tissue) at 14 days postsurgery was measured
using fluorescent microspheres.20 Myocardial capillary and arteriolar densities were
measured at 14 and 30 days postsurgery. EC and cardiomyocyte apoptosis was evaluate at
14 days. Putative cardiomyocyte progenitor cells were identified in myocardial sections as
those cells expressing both c-kit and the cardiomyocyte transcription factor GATA-4.21 The
rate of c-kitpos cell proliferation was determined by double-staining of sections for c-kit and
the cell cycle marker minichromosome maintenance protein (MCM)-2.22
The effect of SCF neutralization on NGF-induced improvement of cardiac function and
angiogenesis was studied at 14 days postoperation.
Analyses of Cardiac Progenitor Cells
Cardiac flow cytometry analyses of LV-resident Linnegc-kitpos and Linnegsca-1pos progenitor
cells were performed at 3 and 14 days (Linnegc-kitpos, only) postoperation. Expression of
TrkA and p75NTR (low-affinity NGF receptor) by isolated c-kitpos cells was evaluated by
RT-PCR. The effect of neutralizing the c-kit receptor ligand SCF on Ad.hNGF-induced
Linnegc-kitpos expansion was assessed at 3 and 14 days postsurgery by flow cytometry.
Expressional Analyses
At 3 days postsurgery, mRNA levels of transgenic (human) NGF and murine NGF, TrkA
and SCF were evaluated in the periinfarct zone. Western blot analyses for V5-tag, TrkA,
total and phospho(Ser473)-Akt, total and phospho(Thr32)-Foxo-3a, total and
phospho(Tyr730)-c-kit, SCF, and GAPDH (loading control) were performed. Human and
murine NGF and SCF levels were measured by ELISA.
Results
NGF and TrkA Expression in the Human Heart
Immunohistochemical analyses detected NGF presence in the human myocardium. As
shown in Figure 1A, according to a semiquantitative analysis, the majority of
cardiomyocytes of both not infarcted hearts and the remote area of infarcted hearts
expressed NGF weakly to moderately. By contrast, most cardiomyocytes in the periinfarct
area express high NGF levels, thus suggesting that NGF is upregulated by ischemia. Figure
1B shows NGF expression in a human infarcted heart. Figure 1C and 1D shows TrkA
expression by cardiomyocytes and ECs in an infarcted heart, respectively.
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Myocardial NGF and TrkA Levels Are Increased by MI in Mice
To confirm that MI increases NGF myocardial expression, we used a mouse MI model. At 3
days post-MI, relative NGF and TrkA mRNA expression in the periinfarct LV increased by
2.0-folds and 4.2-folds in comparison versus sham-operation (Online Figure I, A and B).
Furthermore, protein expression of NGF and TrkA increased in the periinfarct myocardium,
as assessed by ELISA and western blot, respectively (Online Figure I, C and D).
NGF Neutralization Increases Apoptosis, Abrogates Spontaneous Neovascularization, and
Worsens LV Function After MI in Mice
To investigate the role of endogenous NGF in the spontaneous responses to MI, we
neutralized NGF. Postoperation survival of mice was monitored for 14 days. Whereas
survival of sham-operated mice was 100%, mortality in MI mice was significantly
increased, although no differences were observed between MI/Ab-NGF- and MI/goat-IgG-
injected mice (Figure 2A). Importantly, NGF neutralization aggravated the MI-induced
deterioration of cardiac function (Online Table II). In comparisons with non immune goat-
IgG, Ab-NGF further decreased LV pressure (Figure 2B), dP/dtmax (Figure 2C), dP/dtmin
(Figure 2D) and LV ejection fraction (LVEF) (Online Table II). Moreover, Ab-NGF
increased LV chamber volume and LV internal diameter (Online Table II), which are
features of maladaptive LV remodeling. Histological analyses of the periinfarct myocardium
(14 days post-MI) indicated that, in comparison with nonimmune goat-IgG, Ab-NGF
increased apoptosis of ECs (Figure 2E) and cardiomyocyte (Figure 2F), abrogated the
spontaneous capillary growth (Figure 2G), and reduced the density of small (diameter <50
μm) arterioles (Figure 2H).
NGF Overexpression in the Infarcted Myocardium Improves LV Function After MI
To test the therapeutic potential of NGF, we delivered Ad.hNGF or Ad.Null in the mouse
periinfarct myocardium. As expected, at 3 days from Ad.hNGF, human NGF mRNA was
expressed in the mouse LV, with higher expression in the periinfarct zone (Online Figure II,
A). Moreover, the V5-tag was detected in the periinfarct zone of Ad.hNGF-injected mice
(Online Figure II, B). Furthermore, ELISA documented the presence of transgenic NGF in
the plasma of Ad.hNGF-injected MI mice, only (Online Figure II, C).
Importantly, Ad.hNGF reduced mortality at 30 days post-MI (P<0.01 versus MI/Ad.Null;
Figure 3A) and improved LV function at both 14 and 30 days post-MI. In fact, in
comparisons to MI/Ad.Null, at both time points, NGF overexpression increased LV pressure
(Figure 3B), decreased LV end-diastolic pressure (Figure 3C), and improved dP/dtmax and
dP/dtmin (Figure 3D and 3E), as well as LVEF and LV fractional shortening (LVFS) (Figure
3F and 3G). Furthermore, Ad.hNGF reduced systolic LV internal diameter and LV chamber
volume (Figure 3H and 3I), indicating the preventive effect of NGF on post-MI LV chamber
dilatation. All measured functional and dimensional data are reported in Online Table III.
NGF Overexpression Reduces Apoptosis and Improves Angiogenesis and Cardiac
Perfusion
At 14 days post-MI, in comparison with Ad.Null, Ad.hNGF reduced the percentage of
TUNEL-positive apoptotic ECs and cardiomyocytes in the periinfarct area (Figure 4A and
4B). Moreover, Ad.hNGF increased the densities of both capillaries and small (diameter,
<50 μm) arterioles at both 14 and 30 days post-MI and gene transfer (Figure 4C and 4D).
Figure 4E shows mouse myocardial sections were capillaries are stained by isolectin-B4 (red
fluorescence) and arterioles (indicated by arrows) are identified by both isolectin-B4 and α-
smooth muscle actin staining (green fluorescence). The proangiogenic effect of Ad.hNGF
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was associated with improved LV perfusion, as myocardial blood flow was increased to
152% versus MI/Ad.Null (Figure 4F).
NGF Therapeutic Effects Are Regulated by the Akt/Foxo-3a Pathway
Ad.hNGF increased phospho-Akt and phospho–Foxo-3a levels in the periinfarct
myocardium (Figure 5A). Moreover, Ad.hNGF-induced neovascularization (Figure 5B and
5C) and LV function improvement (Figure 5D and 5E) at 14 days post-MI were abolished
by coinjection with Ad.AAAFoxo-3a. All functional and LV dimensional data of this
experiment are reported in the Online Table IV.
NGF Increases the Abundance of c-kitpos the Infarcted Heart
To investigate whether NGF overexpression may increase the myocardial abundance of c-
kitposGATA-4pos, putative cardiomyocyte progenitor cells were counted at 3 days
postsurgery.13,23 Results show that hNGF increases the abundance of c-kitposGATA-4pos
cells in the periinfarct area (Figure 6A), but not in the infarct area (Online Figure III, A). In
addition, Ad.hNGF increased the number of c-kitpos cells in both the periinfarct and the
infarct area at 3 days post-MI (Online Figure III, B). To address whether NGF
overexpression induced proliferation of c-kitpos cells, a double-staining for c-kit and the
proliferation marker MCM-2 was performed. As shown by Figure 6B, proliferating c-kitpos
cells were higher in NGF-engineered hearts. Heart-resident Linnegc-kitpos cells have been
proposed to represent cardiac stem cells.24 To investigate the hypothesis that NGF
overexpression increases the abundance of Linnegc-kitpos cells, flow cytometric analysis of
cardiomyocyte-depleted cardiac cell populations was performed. As shown in Figure 6C, MI
increased the number of Linnegc-kitpos cells. The abundance of Linnegc-kitpos cells was
further enhanced after NGF overexpression. We also evaluated whether Ad.hNGF
selectively enriches for Linnegc-kitpos cells without affecting other putative progenitor cell
populations. To this aim, flow cytometric analysis for Linnegsca-1pos cells was performed at
3 days postsurgery and gene transfer. The percentage of heart-resident Linnegsca-1pos cells
was increased by MI, without being affected by Ad.hNGF (Online Figure III, C), thus
suggesting that NGF activates an enhancement mechanism, which selectively impacts on c-
kitpos cells. To determine whether the increase of Linnegc-kitpos cells was attributable to a
direct effect of NGF on these cells, we evaluated whether heart-resident c-kitpos cells
possess NGF receptors, but RT-PCR showed that neither TrkA nor the NGF low-affinity
p75NTR receptor were expressed (Online Figure IV). As the activation of c-kit receptor
occurs by SCF binding,13,21 we next analyzed whether Ad.hNGF increases SCF levels in
the myocardium and in cultured cardiomyocytes. Real-time RT-PCR showed that Ad.hNGF
increased SCF mRNA in both the mouse infarcted heart (Figure 7A) and rat neonatal
cardiomyocytes (RNCMs) (Online Figure V). Moreover, Western blot analyses showed that
Ad.hNGF increased the myocardial level of the 30-kDa membrane-associated SCF isoform
(Figure 7B).18 ELISA confirmed increased SCF and increased c-kit receptor
phosphorylation in NGF-overexpressing myocardium (Figure 7C and 7D). These findings
suggest that NGF-induced increase in c-kitpos progenitor cells may be dependent on the
enhancement of the SCF ligand/c-kit receptor signaling. To further investigate this
hypothesis, we neutralized SCF in mice with MI or sham-operation and gene transfer. We
verified the efficacy of our SCF neutralization approach by measuring (by ELISA) the LV
amount of immunoreactive SCF, which resulted decreased by Ab-SCF at 3 days post-MI
(Figure 7C). Next, we observed that SCF neutralization prevented the Ad.hNGF-induced
increase in Linnegc-kitpos cells (Figure 7E) and diminished Ad.hNGF-mediated increase in
c-kit phosphorylation (Figure 7D) at 3 days post-MI. These data provide further evidence
that SCF mediates NGF overexpression-induced increase in heart-resident Linnegc-kitpos
cells at 3 days post-MI. The MI- and Ad.hNGF-induced increase in heart-resident Linneg c-
Meloni et al. Page 5
Circ Res. Author manuscript; available in PMC 2010 September 16.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
kitpos cells was not maintained up to 14 days from MI and gene transfer, and it was also not
affected by long-term SCF neutralization (Online Figure VI).
Finally, NGF neutralization did not change the abundance of Linnegc-kitpos cells at 3 or 14
days post-MI (Online Figure VII, A and B), thus suggesting that endogenous factors other
than NGF may support Linnegc-kitpos homeostasis in the infarcted heart.
Blocking SCF-Mediated Increase in Linnegc-kitpos Cells Early After MI Does Not Impair NGF
Therapeutic Effects in MI Mice
To investigate whether the rise in Linnegc-kitpos cells at 3 days post-MI plays a role in NGF
gene therapy-induced therapeutic benefits, we treated mice with the short-term SCF
neutralization protocol, earlier (Figure 7E) shown to prevent NGF-induced increase in
Linnegc-kitpos cells. We did not prolong SCF neutralization because we knew that MI- and
Ad.hNGF-induced initial increase in Linnegc-kitpos cells are not maintained at later time
points (Online Figure VI). Short-term SCF neutralization did not affect the Ad.hNGF-
induced improvement of cardiac function (for LVEF, Online Figure VIII, A; for LVFS,
Online Figure VIII, B; other parameters are not shown) and myocardial angiogenesis
(Online Figure VIII, C) at 14 days post-MI. These results suggest that although NGF
overexpression, via SCF, is able to increase c-kitpos progenitor cells in the infarcted heart,
this response is dispensable for the full therapeutic potential of NGF- based therapy.
Discussion
NGF was initially considered with respect of its neural functions, but we and others have
provided seminal evidence of cardiovascular actions of NGF (for review, see elsewhere25).
The present study has demonstrated a series of novel and important cardiovascular features
of NGF and unveiled the therapeutic potential of this neurotrophin for ischemic heart
disease.
NGF neutralization reduced the native angiogenic response to MI. Spontaneous
neovascularization is one of the compensatory responses through which the infarcted heart
attempts to salvage the spared myocardium.26 In fact, reduced blood flow (ischemia) is
cause of progressive cardiomyocyte and EC depletion by apoptotic death, which contributes
to cardiac dysfunction.2,27 We found apoptosis of both cardiomyocytes and ECs increased
by NGF blockade and this may account for impaired LV function and LV chamber
dilatation observed at 14 days post-MI in Ab-NGF mice.
In consideration of the worsened outcome caused by NGF neutralization, we hypothesized
that intramyocardial NGF gene therapy could preserve cardiomyocyte/ECs viability and
promote reparative processes in the infarcted heart, thereby sustaining cardiac function.
Angiogenesis gene therapy has received severe criticisms, but it still remains a promising
approach to resolve or at least improve ischemic cardiovascular disease.28,29 In our study,
adenovirus-mediated NGF overexpression stimulated angiogenesis at both capillary and
arteriolar levels and reduced apoptosis of ECs and cardiomyocytes in the periinfarct
myocardium. The significant angiogenic effect of NGF was also emphasized by increased
myocardial perfusion in NGF-engineered hearts. The proangiogenic effect of NGF might be
explained by its capacity to directly induce survival, proliferation and migration/invasion of
ECs, all essentials for the angiogenic process. In fact, the capacity of NGF to induce EC
survival and proliferation has been already reported.7,30,31 NGF capacity to promote EC
migration and invasion was also described.32,33
We previously demonstrated that NGF-induced angiogenesis in ischemic limb muscles is
mediated by Akt6 and that NGF promotes in vitro cardiomyocyte survival via the Akt/
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Foxo-3a pathway.9 In line with these previous findings, we show here that overexpressing
NGF increases Akt and Foxo-3a phosphorylation in the myocardium. Importantly,
cotransduction of the MI heart with a mutant form of Foxo-3a which cannot be
phosphorylated by Akt prevented NGF gene therapy-induced improvements in myocardial
angiogenesis and cardiac function. The impact of NGF on the Akt/Foxo-3a pathway may
explain both the proangiogenic and antiapoptotic effects of NGF gene therapy.9,12 In
addition, we have newly identified that NGF increases the expression level of the c-kit
receptor ligand SCF and promotes c-kit phosphorylation in the infarcted heart. SCF
reportedly induces survival, migration, and tube-like structure formation of human fetal
umbilical vein ECs, which express c-kit.34 SCF was also shown to induce
neovascularization in the adult myocardium.18 However, we did not observe c-kit receptor
expression by adult myocardial capillary ECs.35 A possible explanation for this discrepancy
is that SCF-induced neovascularization in adult hearts is exclusively dependent on
vasculogenesis.18 In our study, SCF resulted fundamental for NGF-induced expansion of
heart-resident c-kitpos progenitor cells. Solid experimental evidence originating from the
Anversa laboratory, and confirmed by others, suggests that c-kitpos stem and progenitor cells
participate in the native myocardial repair and regeneration after MI.13,14,36 Few agents
able to modulate in vivo expansion of cardiac c-kitpos cells have been identified to
date14,37; thus, the understanding that NGF is one of such factors represents a novel and
relevant finding in the perspective of therapeutic cardiac regeneration. Heart-derived c-kitpos
cells do not express the mRNA for NGF receptors, thus pinpointing SCF as the mediator of
NGF indirect actions on these cells. In agreement with this theory, SCF promotes
proliferation of c-kitpos cells38 and proliferating c-kitpos cells were increased in the NGF-
engineered infarcted hearts. Of note, SCF neutralization blunted NGF-induced increase in
heart-resident Linnegc-kitpos cells at 3 days post-MI. Furthermore, NGF appears to act
selectively or preferentially on the Linnegc-kitpos cells, because it did not affect the cardiac
abundance of Linnegsca-1pos cells, a different population of putative progenitor cells. We
then tried to rule out the contribution of Linnegc-kitpos cells in the overall therapeutic benefit
induced by NGF gene therapy. To this aim, we used a short-term SCF neutralization
protocol, which proved able to prevent NGF-induced increase in Linnegc-kitpos. Under these
experimental conditions, NGF overexpression maintained its capacity to improve cardiac
function and to promote angiogenesis at 14 days post-MI. This suggests that the increase in
Linnegc-kitpos early after MI is not important for the therapeutic benefit induced by NGF
overexpression. However, we cannot exclude that NGF-induced increase in SCF expression
level and thus in c-kitpos progenitor cells could be utilitarian under different experimental
and clinical circumstances.
In conclusion, this study provides strong evidence for the therapeutic potential of NGF in the
post-MI heart and furthermore reinforces the concept that neurotrophins have important
cardiovascular actions.
Novelty and Significance
What Is Known?
• Nerve growth factor (NGF) is important for the development, homeostasis and
regeneration of the nervous system.
• The TrkA receptor for NGF is present in endothelial cells and cardiomyocytes.
• NGF promotes angiogenesis and cardiomyocyte survival.
What New Information Does This Article Contribute?
• NGF expression is increased in the human and murine infarcted heart.
Meloni et al. Page 7
Circ Res. Author manuscript; available in PMC 2010 September 16.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
• Endogenous NGF promotes angiogenesis and inhibits cardiovascular apoptosis
in the mouse infarcted heart.
• Intramyocardial NGF gene delivery increases post-MI survival and improves
post-MI left ventricular function and remodeling.
• Intramyocardial NGF gene delivery upregulates the expression of stem cell
factor, which is the c-kit receptor ligand, and by this mechanism it enriches the
infarcted heart with Linnegckitpos cardiac progenitor cells.
NGF has historically been implicated in several functions of the nervous system. More
recently, we and others have introduced the new concept that NGF can also elicit
cardiovascular actions, including angiogenesis and cardiomyocyte survival. However,
whether NGF plays a role in the healing of the infarcted heart is unknown. Here we show
that NGF expression is upregulated by myocardial infarction (MI) in both humans and
mice and that endogenous NGF protects the murine infarcted heart by inhibiting
cardiovascular apoptosis and increasing coronary microvasculature. Enhancing this
endogenous mechanism by intramyocardial NGF gene therapy reduces post-MI mortality
and improves left ventricular perfusion, function, and remodeling. This study also
uncovers the previously unknown capacity of NGF to promote expansion of Linnegckitpos
cardiac progenitor cells through an indirect mechanism involving the c-kit receptor
ligand, stem cell factor (SCF). These results reveal novel pleiotropic properties of NGF
and suggest that NGF-based therapy may be a useful approach to alleviate post-MI
remodeling.
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Acknowledgments
We thank Drs Nicolle Kraenkel, Atsuhiko Oikawa, Mauro Siragusa (all from the University of Bristol) and Beatrice
Testa (University of Parma) for technical assistance.
Sources of Funding
The study was supported by British Heart Foundation grants BS/05/ 001 and PG/06/146/21946 (to C.E.).
Non-standard Abbreviations and Acronyms
α-sarc α-sarcomeric actin
Akt serine/threonine-specific protein kinase
EC endothelial cell
Foxo forkhead box-O transcription factors
LV left ventricular
LVEF left ventricular ejection fraction
LVFS left ventricular fractional shortening
MCM minichromosome maintenance protein
MI myocardial infarction
NGF nerve growth factor
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p75NTR p75 neurotrophin receptor
SCF stem cell factor
TrkA tropomyosin-related receptor A
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Figure 1. NGF protein is expressed in the human infarcted heart, with higher expression level in
the periinfarct area
The TrkA receptor of NGF is present in cardiomyocytes and ECs. A, Bar graph represents
the distribution of cardiomyocytes subdivided for their amount of NGF expression. NGF
expression by each cardiomyocyte was determined by a semiquantitative scoring system: no
staining: 0; weak staining: +; weak to moderate staining: ++; strong staining: +++. Data are
expressed as means±SEM. **P<0.01 vs controls without MI; ††P<0.01 vs MI remote area
(n=8 hearts for each group). B, Immunohistochemical staining for NGF in human heart after
acute MI shows an increased protein content (brown) of NGF in the MI border zone
compared to the remote area. Scale bar: 100 μm. C and D, Immunohistochemical detection
of TrkA in human acute MI. The coexpression of TrkA (green fluorescence) in either α-
sarcomeric actin (α-sarc)–positive (red fluorescence) (C) cardiomyocytes or CD34-positive
(red fluorescence) (D) ECs results in yellow fluorescence. A gradient in the TrkA
expression from cardiomyocytes bordering the acute damage (asterisks) is apparent. Nuclei
are recognized by the blue fluorescence of DAPI. Scale bars: 100 μm. TrkA expression in
cardiomyocytes (i inset) and in vascular structures (indicated by white arrows in ii inset),
including capillaries (indicated by white arrows in iii inset) is also shown at higher
magnification. Scale bars: 100 μm.
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Figure 2. NGF neutralization (by Ab-NGF) reduces LV function, increases apoptosis, and
abrogates spontaneous neovascularization at 14 days post-MI
A, Survival of mice after MI or sham operation was monitored for 14 days. B through D,
Bar graphs represent LV pressure (B), dP/dtmax (C), and dP/dtmin (D). E, Bar graph shows
the increased percentage of TUNEL-positive apoptotic ECs in the LV periinfarct area.
Apoptotic ECs (indicated by arrows in the microphotograph) were revealed by TUNEL
(green fluorescence) in combination with the EC marker von Willebrand factor (red
fluorescence). Cardiomyocytes are recognized by α-sarc staining (purple fluorescence).
Scale bars: 10 μm. F, Bar graph shows the increased percentage of TUNEL-positive
apoptotic cardiomyocyte nuclei after Ab-NGF. Apoptotic cardiomyocyte nuclei (indicated
by arrows in the adjacent microphotographs) were revealed by TUNEL-positive (green
fluorescence) in α-sarc-positive (red fluorescence) cardiomyocytes. Nuclei are stained by
DAPI (blue fluorescence). Scale bars: 10 μm. G and H, Bar graphs show the reduced
number of capillaries (G) and arterioles (H) in the LV periinfarct zone. All data are
expressed as means±SEM. *P<0.05 and **P<0.01 vs sham/goat IgG; †P<0.05, ††P<0.01 vs
MI/goat IgG (n=5 mice/group for histological analyses; n=at least 10 mice/group for
hemodynamic analyses).
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Figure 3. NGF overexpression improves post-MI survival and ameliorates LV function at 14 and
30 days post-MI
A, Survival curve shows reduced post-MI mortality of Ad.hNGF-injected mice. B through
E, Bar graphs illustrate the improved LV pressure (B), LV end-diastolic pressure (C), dP/
dtmax (D), and dP/dtmin (E) after Ad.hNGF (analyzed by Millar Tip-catheter). F through I,
Bar graphs show increased LVEF (F) and LVFS (G) and reduced LV internal diameter
(LVID) (H) and LV chamber volume (I) after Ad.hNGF (measured by echocardiography).
Data are expressed as means±SEM. *P<0.05, **P<0.01 vs sham/Ad.Null; †P<0.05,
††P<0.01 vs MI/Ad.Null (n=at least 10 mice/group).
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Figure 4. NGF overexpression inhibits post-MI EC and cardiomyocyte apoptosis and improves
neovascularization and cardiac perfusion
A and B, Bar graphs show reduced percentage of TUNEL-positive apoptotic ECs (A) and
cardiomyocytes (B) in the LV periinfarct zone at 14 days post-MI. C and D, Bar graphs
show increased densities of capillaries (C) and arterioles (D) in the periinfarct area at 14 and
30 days post-MI. E, Representative microphotographs at 14 days post-MI showing
capillaries (stained by isolectin-B4) (red fluorescence) and arterioles (stained by both
isolectin-B4 and α-smooth muscle actin staining [green] and indicated by arrows).
Asterisks indicate the infarct area (scale bar: 50 μm). F, Bar graph shows LV absolute
blood flow at 14 days postsurgery. Data are expressed as means±SEM. *P<0.05, **P<0.01
vs sham/ Ad.Null; †P<0.05, ††P<0.01 vs MI/Ad.Null (n=5 mice/group for histological
analyses; n=10 mice/group for blood flow analyses).
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Figure 5. NGF-induced neovascularization and cardiac function improvement depends on the
Akt/Foxo-3a pathway
A, Western blot analyses show that NGF overexpression induces Akt and Foxo-3a
phosphorylation in the periinfarct myocardium at 3 days postinfarction. GAPDH was used
for loading control. B through E, Bar graphs show that expression of an Akt
phosphorylation-resistant mutant form of Foxo-3a abolished Ad.hNGF-induced
neovascularization (B and C) and prevented Ad.hNGF-induced improvement in LVEF (D)
and LVFS (E) at 14 days post-MI. Data are expressed as means±SEM. *P<0.05 vs sham/
Ad.Null; †P<0.05 vs MI/Ad.Null; ‡P<0.05, ‡‡P<0.01 vs MI/Ad.Null/Ad.Null; §§P<0.01 vs
MI/Ad.Null/Ad.hNGF (n=5 mice/group for Western blot and 6 mice/group for histological
analyses; n=at least 10 mice/group for cardiac function measurements).
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Figure 6. NGF overexpression increases the number of putative c-kitpos progenitor cells in the
mouse infarcted heart
A, Immunostaining for c-kit and GATA-4 in heart sections (c-kit, green fluorescence;
GATA-4, purple dots; α-sarc–positive cardiomyocytes, red; nuclei, blue). c-
kitposGATA-4pos cells are indicated by white arrows. Bar graph represents the number of
c-kitposGATA-4pos cells per millimeter squared of periinfarct myocardium. B,
Immunostaining for proliferating c-kitpos cells in heart sections evaluated by double staining
for c-kit (red fluorescence) and MCM-2 (green). Cardiomyocytes are visualized in yellow
after staining for α-sarc; nuclei are pictured in blue. c-kitposMCM-2pos cells are indicated by
white arrows. Bar graph represents the number of c-kitposMCM-2pos cells per millimeter
squared in the periinfarct area. C, Identification and quantification of cardiac Linnegc-kitpos
cells by flow cytometry. Forward and side scatter (i) shows the total population (in red)
analyzed after LV digestion and cardiomyocyte depletion. For data analysis, counting beads
(purple) were identified by their size (in P4 in the forward and side scatter). ii, Linneg cells
(in P2) were gated from the total population of extracted cells. iii, Negative control (NC) for
c-kitpos cells. iv, Bar graphs and representative microphotographs show the number of
Linnegc-kitpos cells per milligram of LV tissue. The number of c-kitpos cells (in P3) was
analyzed within the Linneg cell population. Data are expressed as means±SEM. *P<0.05,
**P<0.01 vs sham/Ad.Null; †P<0.05, ††P<0.05 vs MI/Ad.Null. All analyses were
performed at 3 days postoperation (n=5 mice/group for histological analyses and 6 mice/
group for flow cytometry).
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Figure 7. NGF-induced increase of c-kitpos progenitor cells in the infarcted heart is mediated by
the SCF/c-kit signaling
All analyses were performed at 3 days postsurgery. A, Bar graph shows increased SCF
mRNA expression in the periinfarct myocardium following NGF gene transfer. B, Western
blot analysis shows the NGF-induced increase in membrane-bound (30-kDa) SCF protein.
GAPDH was used for normalization. C, ELISA performed on LV tissue shows increased
level of immunoreactive SCF after MI and Ad.hNGF. These responses were prevented by
SCF neutralization (by Ab-SCF). D, Representative western blot shows increased c-kit
phosphorylation in Ad.hNGF-injected LV, which is prevented by Ab-SCF. E, Identification
and quantification of cardiac Linnegc-kitpos cells by flow cytometry after SCF neutralization.
In the presence of SCF blockade, the number of Linnegc-kitpos cells per milligram of LV was
not increased by either MI or hNGF gene transfer. Data are expressed as means±SEM.
*P<0.05, **P<0.01 vs sham/Ad.Null; †P<0.05 vs MI/Ad.Null; §P<0.05 vs MI/Ad.hNGF
(n=5 mice/group for PCR and Western blot, 4 mice/group for ELISA and at least 6 mice/
group for flow cytometry).
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